亘利生物科技（上海）有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer 2022-08-01 20:00
Gracell Biotechnologies to Participate in BTIG 2022 Biotechnology Conference 2022-07-26 20:30
Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer 2022-07-19 20:00
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences 2022-06-14 20:00
Gracell Biotechnologies Schedules Clinical Update Call After EHA2022 2022-06-03 23:00
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences 2022-05-19 22:39
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress 2022-05-12 22:01
Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting 2022-04-28 22:30
Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting 2022-04-14 20:30
Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL 2022-04-09 04:00
Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022 2022-03-09 05:30
Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform 2022-02-22 20:30
Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma 2022-02-17 21:30
Gracell Biotechnologies Unveils Innovation Center in U.S. 2022-01-12 21:00
Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index 2021-12-16 21:00
Gracell Biotechnologies Announces Senior Management Team Share Purchase Plan 2021-11-23 22:00
Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma 2021-11-19 19:00
Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting 2021-11-04 21:05
Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors 2021-08-16 20:00
Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma 2021-05-26 21:00
1 2 3 4